Abbvi today
From 13:59 on East
- 52-week range
- $ 153.58
▼
$ 207.32
- Dividend yield
- 3.57%
- P/e ratio.
- 63.85
- Value is valuable
- $ 205.00
Abbvi NYSE: ABBV It is a high -quality pharmaceutical company that grows dividends with reliable growth prospects: now is the time to load shares. Behind him are fears of the Patent cliff of Humira, with Skyrizi, Rinvoq and a diversified portfolio of products gaining speed. Among the critical details from the 4th quarter and the end of the F2024 is that sales of Humira are reduced through solid two-digit and, as the field is expected
We look forward to the fact that the company confirmed the prospects for high-class CAGR, at least over the next four years, the prospects that have a highly accessible diamond with an income of up to 10-time income, by 2030, is too good to miss. Field
ABBVIE is gaining momentum in the world
Investors are worried about the longevity of ABBVIE in the world of the post -sector, they can state their fears in order to relax. The results of Q4 are strong, including 5.6% of the highest level growth, which ahead of consensus forecasts. Growth was observed in most segments with neurobiology leading by 20%, and aesthetics are reduced by 5.2%. Immunology, the main segment, grew by almost 5% under the influence of its new blockbusteers, while oncology, a critical growth avenue, increased by 12%.
Margins news is mixed from the purchased milestones IP/RD, which reduced the results. The company published a loss and adjusted reduction in GAAP, leaving EPS at the level of $ 2.6, not a penny of forecasts. Nevertheless, income and cash flow remain strong enough to maintain the balance of health, capital profitability and solid long -term prospects. It is expected that the impact on research and development will affect the results, moving forward, and achievements in the pipeline lead to the next round of significant issues.
The management is why the price of shares will increase in 2025. The initial leadership of the F2025 is reliable, waiting for $ 12.22 in the adjusted EPS in the range of the middle point. This is 18% higher than the Marketbeat consensus during release, but does not include possible milestones, so it may not be directly comparable. Despite this, if we assume that AIP/RD milestones are 2024 in 2025, the leadership is still better than consensus and positive for investors.
Analysts support the price of ABBVIE shares in 2025
ABBVIE Promotion Forecast Today
$ 205.00
11.47% growthModerate purchase
Based on 24 analysts ratings
| High forecast | $ 225.00 |
|---|---|
| Average forecast | $ 205.00 |
| Low forecast | $ 180.00 |
Abbvi forecast forecast for shares
Analysts mood trends are strong, and coverage increases significantly in the second half of 2024, an increase in the price target price price price and a two -digit increase is indicated. The number of analysts covering shares increased by 60% to 24 in H2 2024, which is significant from the investment dollars that they represent, and the influx caused by their coating. They evaluate the action as a moderate purchase and see that it increases to $ 205 or higher by the end of the year. Institutions provide another fair wind for the market, buying every quarter in balance since 2022 and buying costs more than twice as for the sale.
Capital profitability is one of the reasons why sellers such as this action. Growth prospects, cash flow and balance are supported by a healthy dividend worth about 60% of income and more than 3.5%, while shares are traded near critical support levels.
Abbvie: the rebound is included, the new maximum is possible this year
The ABBVIE market resolutely reacted to news with 5% progress in Premarket trade. This step expands at the beginning of the week and confirms strong support at 170 dollars, consistent with the signal dedicated to the trend. Stochastic and MACD -indicators exacerbate the signal, aligning the partition market within the rising trend, ready for the next bull swinging. The price of ABBV shares can quickly switch to the level of $ 200 and set a new maximum in this scenario, but at first it should cross the level of 186.50 US dollars and close the gap that was formed at the end of 2024.
Before considering ABBVIE, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market conquers … And Abbvi was not on the list.
While ABBVIE is currently undergoing a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Enter your email address, and we will send you a list of 10 best promotions for owning in 2025 and why they should be in your portfolio.
Get this free report